Publication: Novedades terapéuticas en la era de la multirresistencia antibiótica a propósito de un estudio de utilización
de ceftazidima/avibactam
Loading...
Official URL
Full text at PDC
Publication Date
2018-02
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
La crisis sanitaria a la que se enfrenta la sociedad desde hace algunos años está dando paso a la era de la multirresistencia, donde microorganismos que fueron fácilmente combatidos gracias a los primeros antibióticos, ahora son causantes de infecciones para las que las alternativas terapéuticas han sido agotadas. En parte ha contribuido a ello el mal uso de los antibióticos, por lo que se han propuesto estrategias para optimizar la prescripción de estos antimicrobianos, como es el caso de los PROA y así reducir al máximo el desarrollo de resistencias y conseguir un éxito mayor en el tratamiento de las infecciones bacteriana. Por otro lado, no favorece la resolución de la crisis antes mencionada la escasa comercialización de nuevos antibióticos en la última década.
Recientemente se han comercializado 4 nuevos antibióticos que pueden ayudar en este problema, Dalbavancina, Tedizolid, eftolozano/Tazobactam y Ceftazidima/Avibactam. De este último se ha llevado a cabo un estudio de utilización en el Hospital Universitario La Paz de Madrid donde participaron 8 pacientes de distintos servicios clínicos, todos ellos padecían una infección para la que el tratamiento establecido no estaba resultando efectivo. Los resultados obtenidos en este estudio se resumen en que la infección se resolvió en el 75% de los casos. Por lo tanto parece indispensable no solo un uso más responsable de los antibióticos sino el desarrollo de otros que aporten nuevas alternativas terapéuticas.
Since pathogenic microorganisms which were combated in the past are now responsible for infections whose therapeutic options have been exhausted, the society is undergoing a serious health crisis where multirresistance prevails. A bad antibiotic prescription could be one of the main causes in the development of antibiotic resistance and it could be improved by PROA so this resistant infections can be prevented and even enhance antibiotic treatments. On the other hand, this situation hardly gets solved due to the fact that few antibiotics have been recently approved like Dalbavancina, Tedizolid, Ceftolozano/Tazobactan or Ceftazidima/Avibactam. The last one mentioned has been considered in a drug use evaluation in the Hospital Universitario La Paz de Madrid. 8 pacients from the hospital have participated in this evaluation and all of them had an infection whose previous treatment wasn’t succesful. It ended up with the 75% of the cases resolved. Thus, it seems essential not only to make a responsible use of antibiotics but also to promote the development of new antibiotics.
Since pathogenic microorganisms which were combated in the past are now responsible for infections whose therapeutic options have been exhausted, the society is undergoing a serious health crisis where multirresistance prevails. A bad antibiotic prescription could be one of the main causes in the development of antibiotic resistance and it could be improved by PROA so this resistant infections can be prevented and even enhance antibiotic treatments. On the other hand, this situation hardly gets solved due to the fact that few antibiotics have been recently approved like Dalbavancina, Tedizolid, Ceftolozano/Tazobactan or Ceftazidima/Avibactam. The last one mentioned has been considered in a drug use evaluation in the Hospital Universitario La Paz de Madrid. 8 pacients from the hospital have participated in this evaluation and all of them had an infection whose previous treatment wasn’t succesful. It ended up with the 75% of the cases resolved. Thus, it seems essential not only to make a responsible use of antibiotics but also to promote the development of new antibiotics.